Cannabinoid compounds protected brain cells from damage caused by high glucose and Alzheimer's-linked proteins | Research

The takeaway

Five cannabinoid agents, including endocannabinoids and synthetic cannabinoids, protected rat hippocampal neurons from combined hyperglycemia and amyloid beta toxicity, with the FAAH inhibitor URB597 showing the highest efficacy.

Researchers interested in neurodegenerative disease, the endocannabinoid system, and neuroprotection strategies.

FAAH inhibitor URB597 showed the highest neuroprotective efficacy

What the researchers found

All five cannabinoid agents preserved cell viability, stimulated mitochondrial membrane potential, and reduced oxidative damage and inflammation. URB597, which blocks the enzyme that breaks down endocannabinoids, was the most effective.

Why it matters

Hyperglycemia and amyloid beta are both implicated in Alzheimer's disease, and this study suggests the endocannabinoid system could be a therapeutic target for neuroprotection in conditions where both are present.

The numbers in context

Five agents tested: AEA, 2-AG, CP 55-940, WIN 55,212-2, and URB597. Concentrations ranged from 1 nM to 1 μM. Treatment with 150 mM glucose followed by 500 nM amyloid beta 1-42.

How the study worked

Cell culture study using primary rat hippocampal neurons exposed to a combined insult of high glucose (150 mM) plus amyloid beta 1-42 peptide (500 nM). Five cannabinoid agents were tested at concentrations from 1 nM to 1 μM.

What this study cannot tell us

This is a cell culture study using rat neurons, not a whole-animal or human study. The combined insult model, while relevant, is an artificial simulation of Alzheimer's disease pathology.

How to read the evidence

Preliminary: cell culture study in rat neurons, not yet tested in animals or humans.

When this study was published

Published in 2020 in Neurochemistry International.

The bigger picture

The finding that boosting endocannabinoid levels (via FAAH inhibition) was more protective than direct cannabinoid receptor activation suggests that enhancing the body's own cannabinoid system may be a promising approach for neurodegenerative conditions.

Questions still open

Would FAAH inhibitors show similar neuroprotective effects in animal models of Alzheimer's disease? Could these findings translate to clinical interventions for patients with diabetes-related cognitive decline?

Common questions

What made the FAAH inhibitor more effective than direct cannabinoids?

URB597 blocks the enzyme that breaks down the body's own endocannabinoids, effectively boosting them system-wide. This approach appeared to activate the Nrf2 antioxidant pathway differently than direct receptor activation.

What is the connection between diabetes and Alzheimer's?

High blood sugar (hyperglycemia) can induce oxidative stress, inflammation, and mitochondrial dysfunction in brain cells, all of which overlap with mechanisms involved in Alzheimer's disease progression.

Read the original research

Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+Aβ1-42 peptide in rat hippocampal neurons.

Neurochemistry international, 140, 104817

View on PubMed ↗Publisher’s paper ↗

Citation

Elmazoglu, Zubeyir; Rangel-López, Edgar; Medina-Campos, Omar Noel; Pedraza-Chaverri, José; Túnez, Isaac; Aschner, Michael; Santamaría, Abel; Karasu, Çimen. (2020). Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+Aβ1-42 peptide in rat hippocampal neurons.. Neurochemistry international, 140, 104817. https://doi.org/10.1016/j.neuint.2020.104817